Inhibrx Biosciences (INBX) Net Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Net Margin data on file, last reported at 2204.15% in Q2 2025.

• On a quarterly basis, Net Margin fell 186021515.0% year-over-year to 2204.15% in Q2 2025; TTM through Dec 2025 was 10003.93%, a 10201985.0% decrease from a year earlier, with the FY2025 full-year figure at 10773.46%, down 85455946.0% from the prior year.
• Net Margin for Q2 2025 stood at 2204.15%, up from 47865.0% in the prior quarter.
• Over the last five years, Net Margin for INBX reached as high as 1858011.0% in Q2 2024 and fell as low as 156840.0% in Q2 2023.
• Historically, Net Margin has averaged 266992.19% across 3 years, with a median of 24574.34% in 2023.
• Across the five-year window, Net Margin soared 201485100 bps in 2024 and plunged 186021515 bps in 2025, its largest moves.
• Year by year, Net Margin stood at 5628.52% in 2023, then sank by 750 bps to 47865.0% in 2024, then surged by 95 bps to 2204.15% in 2025.
• Per Business Quant data, the three most recent Net Margin figures were 2204.15% in Q2 2025, 47865.0% in Q4 2024, and 1858011.0% in Q2 2024.